Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.

Artificial intelligence stands out as a particularly promising solution to the challenges of improving health literacy.